Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 88.955 USD 0.83%
Market Cap: 9.4B USD
Have any thoughts about
Intra-Cellular Therapies Inc?
Write Note

Relative Value

The Relative Value of one ITCI stock under the Base Case scenario is 40.74 USD. Compared to the current market price of 88.955 USD, Intra-Cellular Therapies Inc is Overvalued by 54%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ITCI Relative Value
Base Case
40.74 USD
Overvaluation 54%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
69
vs Industry
11
Median 3Y
18.1
Median 5Y
35.3
Industry
2.6
Forward
13.7
vs History
vs Industry
Median 3Y
-25
Median 5Y
-15.1
Industry
23
Forward
-128
vs History
vs Industry
Median 3Y
-23
Median 5Y
-15.3
Industry
17.8
vs History
vs Industry
Median 3Y
-23
Median 5Y
-15.3
Industry
25.4
vs History
28
vs Industry
6
Median 3Y
8
Median 5Y
6.7
Industry
2.2
vs History
73
vs Industry
11
Median 3Y
15.8
Median 5Y
30.4
Industry
2.8
Forward
12.2
vs History
68
vs Industry
12
Median 3Y
17.1
Median 5Y
22
Industry
5.4
vs History
vs Industry
Median 3Y
-21.6
Median 5Y
-13
Industry
13.7
Forward
-76
vs History
vs Industry
Median 3Y
-21.6
Median 5Y
-13
Industry
17.2
Forward
-81.1
vs History
vs Industry
Median 3Y
-20.9
Median 5Y
-13.5
Industry
16.5
vs History
vs Industry
Median 3Y
-20.8
Median 5Y
-13.5
Industry
19.3
vs History
66
vs Industry
4
Median 3Y
27.9
Median 5Y
30.8
Industry
2

Multiples Across Competitors

ITCI Competitors Multiples
Intra-Cellular Therapies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
9.4B USD 15.4 -109.2 -69.5 -69.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
761.8B USD 18.5 90.9 48.9 54.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.4 27.8
US
Johnson & Johnson
NYSE:JNJ
368.4B USD 4.2 25 12.1 15.8
US
Merck & Co Inc
NYSE:MRK
250.9B USD 4 20.6 10.4 12.5
CH
Roche Holding AG
SIX:ROG
208.8B CHF 3.6 18.2 10.2 12.1
CH
Novartis AG
SIX:NOVN
181.2B CHF 4.2 12.6 10 14.9
UK
AstraZeneca PLC
LSE:AZN
158.6B GBP 4.1 31.3 169.3 253.7
IE
Endo International PLC
LSE:0Y5F
155B USD 66.9 -53 248.3 622.6
P/E Multiple
Earnings Growth
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Average P/E: 33.4
Negative Multiple: -109.2
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
90.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25
-22%
US
Merck & Co Inc
NYSE:MRK
20.6
7 336%
CH
Roche Holding AG
SIX:ROG
18.2
32%
CH
Novartis AG
SIX:NOVN
12.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.3
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -53 N/A

See Also

Discover More
Back to Top